Pyxis Oncology is a biotechnology business based in the US. Pyxis Oncology shares (PYXS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.07 – a decrease of 10.08% over the previous week. Pyxis Oncology employs 44 staff and has a trailing 12-month revenue of around $16.1 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.07 |
|---|---|
| 52-week range | $0.83 - $5.39 |
| 50-day moving average | $1.07 |
| 200-day moving average | $2.38 |
| Wall St. target price | $6.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.32 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.07 from 2025-05-09
| 1 week (2025-05-05) | -10.08% |
|---|---|
| 1 month (2025-04-11) | 11.61% |
| 3 months (2025-02-12) | -16.41% |
| 6 months (2024-11-12) | -76.84% |
| 1 year (2024-05-10) | -75.35% |
|---|---|
| 2 years (2023-05-11) | -64.80% |
| 3 years (2022-05-11) | 2.12 |
| 5 years (2020-05-08) | N/A |
| Revenue TTM | $16.1 million |
|---|---|
| Gross profit TTM | $15.7 million |
| Return on assets TTM | -24.77% |
| Return on equity TTM | -62.76% |
| Profit margin | 0% |
| Book value | $2.01 |
| Market Capitalization | $78.1 million |
TTM: trailing 12 months
We're not expecting Pyxis Oncology to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Pyxis Oncology's shares have ranged in value from as little as $0.8332 up to $5.3899. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pyxis Oncology's is 1.148. This would suggest that Pyxis Oncology's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put Pyxis Oncology's beta into context you can compare it against those of similar companies.
Pyxis Oncology, Inc. , a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate.
We dug through 60 years of Berkshire Hathaway annual shareholder letters to bring you 9 lessons from Warren Buffett: “The Oracle of Omaha.”
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Thinking of switching from Moomoo? Here are 5 apps like Moomoo that offer valuable benefits
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.